<DOC>
	<DOCNO>NCT01359657</DOCNO>
	<brief_summary>The purpose study determine 1 ) safety tolerability multiple intravenous dos anti-CXCR4 ( BMS-936564 ) monotherapy combination , 2 ) maximum tolerate dose ( MTD ) BMS-936564 combination Lenalidomide/Dexamethasone Bortezomib/Dexamethasone subject relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Anti-CXCR4 ( BMS-936564 ) Alone Combination With Lenalidomide/Dexamethasone Bortezomib/Dexamethasone Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects must confirm diagnosis multiple myeloma measurable disease Excluded subject plasmacytoma , plasma cell leukemia , nonsecretory myeloma . Disease must assess within 28 day prior treatment initiation . Subjects must evidence relapse relapsed/refractory disease . Subjects must receive least 2 prior regimen multiple myeloma . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . Subjects must receive last treatment ( ie , chemotherapy , radiotherapy , biological , immunotherapy investigational agent [ therapeutic diagnostic ] ) least 14 day prior treatment initiation . The last treatment systemically absorbed steroid must least 2 week 5 half life ( whichever short ) first dose BMS936564 . A serious uncontrolled medical disorder active infection . Current recent ( within 3 month ) gastrointestinal disease condition could impact absorption orallyadministered drug . Inability swallow oral medication . Uncontrolled significant heart disease . Any malignancy , exclude basal squamous cell carcinoma skin , cervical carcinoma situ , localized prostate cancer , superficial bladder cancer stage 0 , subject diseasefree least 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>